$33.2-million modernization now complete
MONTREAL, Oct. 25, 2011 /CNW Telbec/ - Merck Canada has announced the
completion of a $33.2-million modernization of its Pointe Claire
manufacturing facility that establishes it as a Centre of Excellence
for manufacturing liquids, ointments and creams.
The investment has resulted in the expansion of the plant and
installation of state-of-the-art production equipment, as well as the
refit of production and storage areas, increasing the facility's
competitiveness internationally while preserving local jobs.
"Merck's decision to invest $33.2 million is a testimony to its
employees as well as an acknowledgement of the quality of the workforce
at the Pointe Claire plant," said Merck Canada President and Managing
Director Cyril Schiever. "The investment has allowed us to install
cutting-edge technology and improve the facility's efficiency."
"Quebec has targeted the biopharmaceutical industry as a prime economic
lever and is working to stimulate investment in this sector," said Sam
Hamad, the Minister for Economic Development, Innovation and Export
Trade as well as the minister responsible for the Quebec City region.
"Today's announcement shows that we have the economic and strategic
assets to ensure growth in this industry. Quebec will continue to be an
investment-friendly jurisdiction for all biopharmaceutical companies."
The modernization project began with the construction of a new
56,500-square-foot modern warehouse, which then allowed the former
warehouse to be refitted, and extra manufacturing and packaging lines
to be installed.
Seven liquid, ointment and cream filling lines, along with new
equipment, were subsequently installed. These facilities will enable
the production of 14 new products totalling eight million units per
The Pointe Claire plant is one of the facilities in Merck's global
network outside of the United States to have received QSP-2
certification from the U.S. Food and Drug Administration, which permits
Canadian products to be exported to the U.S.
In total, $20 million of the overall investment went toward the purchase
of goods and services from Quebec suppliers. The Pointe Claire plant
employs 264 people.
Today's Merck is working to help the world be well. Merck is a global
health care leader with a diversified portfolio of prescription
medicines, vaccines, consumer and animal health products. In Canada,
Merck markets over 530 pharmaceutical, consumer and animal health
products and is a leader in a broad range of areas such as cardiology,
immunology, infectious diseases, respiratory, vaccines, women's health
and sun care. It is also focused on expanding offerings in other areas,
including virology, oncology and diabetes.
Merck is one of the top R&D investors in Canada, with an investment of
$78.6 million in 2010. Merck also has a large manufacturing facility in
Québec dedicated to the annual production of some 35 million units
including the Claritin® and Aerius® brands. Based in Montreal, Quebec,
Merck employs over 1,400 people across Canada. For more information
about our operations in Canada, visit www.merck.ca.
For further information:
| Marc Osborne |
| || Emmanuelle Vatel |
(514) 395 0375 x234